Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

3 hours ago 6

In Brief

Posted:

6:50 AM PST · November 17, 2026

Demis Hassabis, main  enforcement  serviceman  of DeepMind TechnologiesImage Credits:Jose Sarmento Matos/Bloomberg / Getty Images
  • Ram Iyer

Isomorphic Labs, the AI drug-discovery level that was spun retired of Google’s DeepMind successful 2021, has raised $5 cardinal successful a Series C backing circular arsenic it seeks to instrumentality its cause candidates to objective trials.

The backing was co-led by Greenoaks and Sequoia Capital, with caller capitalist Andreessen Horowitz and different investors besides participating. All of the company’s existing backers, including Alphabet’s task divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, besides invested.

Isomorphic Labs builds an AI drug-design motor that uses a slew of simulation AI models that research assorted areas of chemistry to assistance the institution plan drugs. The company, whose enactment builds connected DeepMind’s breakthrough AlphaFold protein-folding AI model, said its programme has yielded “positive preclinical results” successful oncology and immunology. The laboratory has struck deals with pharma giants similar Eli Lilly, Novartis, and Johnson & Johnson.

The caller funding, which comes connected the heels of a $2.1 cardinal Series B circular successful May, volition beryllium utilized to proceed processing its drug-design engine, arsenic good arsenic to foray into much types of medicine.

The Series C is Isomorphic’s archetypal fundraise since its laminitis and CEO, Demis Hassabis, near his presumption arsenic caput of DeepMind to absorption connected cause discovery, which besides saw him moving into a president relation astatine DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize successful chemistry for the lab’s enactment connected AlphaFold, a strategy that predicts the 3D operation of proteins with thing much than their familial sequence.

Isomorphic did not disclose its caller valuation. Bloomberg reported earlier this period that the laboratory was looking to rise backing astatine a $50 cardinal valuation.

Subscribe for the industry’s biggest tech news

Latest successful Biotech & Health

Read Entire Article